Although the hyper-glycosylated transmembrane protein Mucin 1 (MUC1) is aberrantly overexpressed in human breast carcinoma, the biological significance of MUC1 overexpression is unclear. This study showed that MUC1 expression promoted the synthesis and secretion of vascular endothelial growth factor (VEGF) through the AKT signaling pathway. Increase VEGF production through MUC1 expression had a number of effect. First, MUC1 transfection increased expression of VEGF in breast cancer cells. Second, MUC1-mediated VEGF induction was attenuated by a chemical inhibitor of AKT or MUC1 knock-down by MUC1 siRNA. Third, MUC1 expression led to the activation of insulin-like growth factor-1 receptor, which correlated with VEGF expression. In addition, when MDA-MB-231 human breast cancer cells were directly injected into NOD/SCID mice, MUC1 expression accelerated xenograft tumor growth in vivo. Finally, MUC1 expression enhanced tumor growth and angiogenesis in a PyMT-MMTV/ hMUC1 transgenic mouse model. Concurrent with these results, analysis of a human tissue microarray identified a high correlation between MUC1 and VEGF expression in human breast carcinoma. The current report is the first to demonstrate that MUC1 expression promotes angiogenesis in human breast cancer in vivo and in vitro.
Introduction
Breast cancer is the most common cancer among women worldwide, and >1 million women are diagnosed with breast cancer every year. Although breast cancer is one of leading causes of cancer deaths in the United States and the world (Jemal et al., 2010) , the biology of breast cancer is not fully understood. A number of molecules have been studied, but most of them show ambiguous prognostic value or are not applicable to patient treatment.
Mucin 1 (MUC1), a type I transmembrane protein, is a large (MW 4250 000 Da) glycoprotein expressed on the apical surface of most normal secretory epithelial cells, including those of the mammary gland, and the gastrointestinal, respiratory, urinary and reproductive tracts (Gendler, 2001; Brayman et al., 2004) . MUC1 and other mucins form a physical barrier that protects epithelia from damage induced by exposure to the external environment (Duraisamy et al., 2007) . In malignancies, MUC1 is overexpressed on the entire cell surface with up to 90% of carcinomas showing have aberrant MUC1 expression (Gendler et al., 1990; Sakamoto et al., 1997) . MUC1 overexpression correlates with high metastatic potential and poor survival; therefore, MUC1 antigens have been used as clinical markers to monitor disease progression in cancer patients (Kohno et al., 1992; Duffy et al., 2000) . In addition, previous studies have shown that MUC1 has a pivotal role in tumor development, growth, invasion (Sachdeva and Mo, 2010) , oncogenic cellular signal transduction (Raina et al., 2004; Wei et al., 2006) , responses to hypoxia (Mikami et al., 2009 ) and resistance to anti-cancer reagents (Fessler et al., 2009) . However, the significance of high expression of MUC1 in tumor cells remains to be determined.
Angiogenesis, the formation of new blood capillary vessels from pre-existing vasculature, is extremely important during embryonic development (Wang et al., 2009) for the maintenance of the vertebrate body (Risau, 1997) . Vascular endothelial growth factor (VEGF) is the most important angiogenic factor (Leung et al., 1989) . VEGF has been shown to be essential for experimental tumorigenesis (Borgstrom et al., 1996; Yoshiji et al., 1997) and is expressed in different types of human cancers (Dvorak et al., 1999) . Modulation of VEGF expression is complex because VEGF is controlled by numerous cytokines and growth factors, including endothelial growth factor, transforming growth factor-a, transforming growth factor-b, insulinlike growth factor 1 (IGF-1), fibroblast growth factor, platelet-derived growth factor and interleukin-6, which regulate VEGF expression in different cell types at multiple levels (Ben-Av et al., 1995; Frank et al., 1995; Li et al., 1995; Cohen et al., 1996) . Moreover, hypoxia is the factor that induces the highest level of VEGF induction. However, many cell lines express high levels of VEGF under normoxic conditions, indicating that other factors can also have a role in regulating VEGF (Feldkamp et al., 1999) . Interestingly, the phosphatidylinositol 3-kinase pathway is also highly important in human fibrosarcomas and renal cell carcinomas for driving VEGF transcription under normoxic conditions through activation of protein kinase C z, (Pore et al, 2004) .
In previous studies, it has been shown that MUC1 expression and angiogenesis are correlated in breast, lung and prostate cancer (Giatromanolaki et al., 2000; Papadopoulos et al., 2001; Hattrup and Gendler, 2006) . However, the role of MUC1 expression in breast cancer angiogenesis is still unclear. In the present report we hypothesize that there is a functional link between MUC1 and angiogenesis, and suggest that MUC1 has a complex role in tumor growth. We used several molecular biological approaches to identify the crucial role of MUC1 during tumor angiogenesis. We subsequently demonstrated that activation of the IGF-1R and phosphatidylinositol 3-kinase/AKT pathways via MUC1 overexpression is a crucial event for the regulation of VEGF, one of the pivotal genes implicated in angiogenesis.
Results

MUC1 expression upregulates the level of VEGF
Numerous reports have documented that MUC1 alters cancer cell growth and tumor development (Gendler, 2001 ). However, most prior studies were conducted using cancer cells. We postulated that MUC1 might have a key role in tumor microenvironment modulation, such as angiogenesis. In preliminary studies we overexpressed MUC1 in HEK-293A cells to evaluate whether MUC1 changes the level of VEGF expression because this is the most important angiogenic factor in normal and cancer cells (Ferrara, 2002) . To evaluate the effect of MUC1 on the levels of VEGF mRNA and protein, we transiently transfected in HEK-293A cells with pcDNA3 or pcDNA3-hMUC1 to express human MUC1, and cell lysates were subjected to semiquantitative reverse transcription-PCR and western blotting. We found that the levels of VEGF protein and mRNA were substantially increased in MUC1-transfected HEK-293A cells compared with pcDNA3-transfected mock control cells (Figure 1a ). The levels of actin protein and mRNA were used as an internal control. To further examine the relationship between MUC1 and VEGF in human breast cancer, two human breast cancer cell lines (MDA-MB-231 and T47D) were transfected with human MUC1 cDNA or empty retrovirus. After transfection, we established stable cell lines expressing MUC1 on the cell surface membrane Protein lysates and RNA were isolated 48 h later. Lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting was performed. VEGF mRNA levels were measured by reverse transcription (RT)-PCR. Actin was used as a control. (b) MDA-MB-231 and T47D human breast adenocarcinoma cells were stably transfected with MUC1. Lysates were separated by SDS-PAGE and western blotting was performed. Total RNA was processed by RT-PCR to measure the VEGF mRNA level. Actin was used as a control. (c) FACS analysis showed cell surface hMUC-1 protein expression level.
( Figure 1c ), and the cell lines were designated as Re/EV and Re/hMUC1. We defined the level of VEGF expression of Re/hMUC1 clones as high compared with Re/EV clones ( Figure 1b) . We found that the RNA level of VEGF was increased in MUC1 stable transfectants (Figure 1b) . On the other hand, the levels of epithelialmesenchymal transition-related E-cadherin, vimentin and angiogenesis-related basic fibroblast growth factor, angiopoietin-1, angiopoietin-2, metastasis-related matrix metalloproteinase 1, matrix metalloproteinase 3, urokinase-type plasminogen activator receptor or urokinase-type plasminogen activator were not changed by MUC1 overexpression (Supplementary Figure S1) . We next measured the amount of VEGF secreted into the conditioned medium from the Re/EV and Re/ hMUC1 clones. MDA-MB-231 and T47D Re/hMUC1 clones markedly increased the amount of VEGF secreted into the conditioned media compared with the Re/EV clones ( Figure 2a ). In addition, we determined whether secreted VEGF affected the proliferation of a murine endothelial cell line, SVEC. SVEC was generated by transforming mouse lymphoid vein endothelial cells with the SV40 large T-antigen. Proliferation of SVEC cells may be enhanced by human VEGF (Sorokin et al., 1997; Yu et al., 2007) . We prepared conditioned media from MDA-MB-231 Re/EV and Re/hMUC1 clones, and treated the SVEC cells with the conditioned media. We then performed a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay to measure cell proliferation rate and performed a trans-well migration assay. We observed that the conditioned media from the MDA-MB-231 Re/hMUC1 clones enhanced the SVEC proliferation rate and migration compared with the conditioned media from the Re/EV clone (Figures 2b  and c) . These data suggest that increased VEGF secretion has an effect on SVEC growth and migration in vitro.
MUC1 expression affects the phosphorylation of AKT and extracellular signal-regulated kinase (ERK) 1/2 Because MUC1 expression affects VEGF expression under normoxic conditions in HEK-293A and human breast cancer cells, the signal transduction pathway might be related to MUC1-mediated VEGF induction (Milanini-Mongiat et al., 2002; Pore et al., 2004) . Thus, we investigated whether the AKT and ERK1/2 pathways could be directly activated by MUC1. For this purpose, we performed western blotting to detect the activation of AKT and ERK1/2 in cell lines overexpressing MUC1. We found that HEK-293A cells transfected pcDNA3-hMUC1 showed significant phosphorylation of AKT and ERK1/2 compared with pcDNA3-transfected HEK-293A cells (Figure 3a) . We also determined whether AKT and ERK1/2 are phosphorylated in stable breast cancer cell clones expressing MUC1 (MDA-MB-231 and T47D). We observed that the levels of phosphorylated AKT and ERK1/2 were significantly increased in each RE/ hMUC1 cell clone ( Figure 3b ).
Activated AKT regulates VEGF expression
As shown in Figures 3a and b, overexpressed MUC1 activated AKT and ERK1/2. To determine whether the AKT or ERK1/2 signaling pathway mediated VEGF expression induced by MUC1, we treated cells with the AKT inhibitor LY-294002 (10 mM, Assay Designs; Ann Arbor, MI, USA) or the ERK1/2 inhibitor PD-98059 (20 mM, Assay Designs) for 24 h and subjected the cell lysates to western blotting. We observed that VEGF expression was significantly downregulated by LY-294002 treatment, suggesting a critical role of the AKT pathway in regulating VEGF production through MUC1 expression. In contrast, PD-98059 treatment had no inhibitory effect on MUC1-induced VEGF expression (Figures 3c and d). We next evaluated the effect of the inhibitor on SVEC proliferation by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Compared with dimethyl sulfoxide-treated conditioned medium, SVEC cell proliferation was obviously suppressed by the conditioned medium treated with LY-294002. The antiproliferative effect of this reagent was stronger than that of PD-98059 ( Figure 3e ).
Although MUC1 expression activated ERK, it appeared that PD-98059 did not attenuate MUC1-induced constructs. After 48 h, lysates were recovered, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blotting was performed to measure phosphorylated AKT (pAKT) and ERK1/2 (pERK). The level of total AKT, ERK and actin was used as an internal and loading control. (b) MDA-MB-231, T47D and MUC1-expressing human breast cancer clones were submitted to western blotting to measure pAKT and pERK levels (c, d). Cells were treated with LY-294002 (10 mM) or PD-98059 (20 mM) for 24 h. Cell lysates were recovered and submitted to western blotting. The levels of VEGF, pAKT, pERK, AKT and ERK were determined by western blotting. (c) HEK-293A and (d) MDA-MB 231 MUC1-expressing human breast cancer clones. (e) SVEC cells were cultured in serum-free cultured medium from inhibitor treated MDA-MB-231 cells-expressing MUC1. Cell proliferation was estimated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The average measurement from four wells at each time point was used to obtain a growth curve. The values are given as the mean ± s.d. Significant differences were evaluated using an unpaired two-tailed Student's t-test. ***Po0.001 compared with DMSO control.
VEGF expression, suggesting that the ERK pathway was less important for VEGF expression induced by MUC1.
MUC1 induces the phosphorylation of IGF-1R
To identify the upstream signaling molecules that could be affected by MUC1, we next examined the effect of MUC1 expression on IGF-1R phosphorylation. It has been reported that IGF-1R is closely related with VEGF expression in cancer cells under hypoxic or normoxic conditions (Yuen et al., 2007; Kurmasheva et al., 2009) . To determine the correlation between MUC1 and IGF-1R, we transiently transfected HEK-293A and human breast cancer cell lines (HS578T and MDA-MB-231) with the pcDNA3-hMUC1 construct and measured IGF-1R phosphorylation. Figure 4a shows that MUC1 expression induced the phosphorylation of IGF-1R in three different cell lines, suggesting the involvement of IGF-1R in the MUC1-mediated cellular signaling pathway. Moreover, as shown in Figure 4b , the phosphorylation of IGF-1R was also increased in MDA-MB-231 clones stably expressing MUC1 compared with the Re/EV clone.
We hypothesized that stable expression of MUC1 mediating increased VEGF expression and IGF-1R phosphorylation would be attenuated by MUC1 siRNA. As expected, MUC1 siRNA inhibited the expression of VEGF, as well as IGF-1R phosphorylation in MDA-MB-231 clones the expressing MUC1 (Figure 4c) . To confirm the hypothesis that IGF-1R phosphorylation is regulated by MUC1 expression, we transfected MCF-7 and T47D, which are endogenous MUC1-expressing human breast cancer cell lines with MUC1 siRNA. Figure 4d shows that MUC1 inhibition by transfection with MUC1 siRNA attenuated endogenous VEGF expression and IGF-1R phosphorylation. This suggests that the IGF-1R signaling pathway communicates with hMUC1. Furthermore, IGF-1R gene knock-down may block MUC1 signaling and VEGF expression. We therefore investigated the effect of IGF-1R siRNA on VEGF expression and AKT phosphorylation in the MDA-MB-231 Re/hMUC1 clones. Figure 4e shows that hMUC1-mediated VEGF expression and AKT phosphorylation were attenuated by IGF-1R knock-down.
MDA-MB-231
Re These data demonstrated that MUC1 induces VEGF expression and this event was associated with activation of IGF-1R. Our findings provide further evidence that phosphorylation of IGF-1R is an important part of the MUC1-mediated signaling pathway.
MUC1 enhances xenograft tumor growth in NOD/SCID mice To determine the effect of MUC1 on tumor growth in vivo, MDA-MB-231 clone (Re/hMUC1#2; n ¼ 5) expressing MUC1 or mock control clone (Re/EV; n ¼ 4) cells were injected directly into NOD/SCID mice at right side of the posterior lateral trunk to generate a tumor nodule. Each tumor was measured once or twice weekly for 7 weeks in two dimensions with electric calipers, and the tumor volume was calculated (Lee et al., 2005) . Xenograft tumor growth was significantly different between the Re/EV and Re/hMUC1#2 clones ( Figure 5a ). Tumor weight was also determined with a surrogate tumor nodule (Figure 5b ). Staining the tumor with antibodies against hMUC1, pIGF-1R and VEGF further demonstrated that the growing tumors maintained expression of pIGF-1R and VEGF (Figure 5c ).
In agreement with these results, we also found a significant increase of tumor growth associated with the Re/hMUC1#2 clone compared with the Re/EV clone. These results support the hypothesis that MUC1 regulates in vivo growth of breast cancer.
Spontaneous mouse breast cancer growth and angiogenesis are regulated by human MUC1 To further assess the role of MUC1 on tumor growth and angiogenic activity, we developed MMTV-PyMT/ hMUC1 double-transgenic mice. MMTV-PyMT/hMUC1 mice spontaneous developed mammary tumors and human MUC1 was expressed in the mammary glands. Two groups of mice were generated by mating with male MMTV-PyMT and female hMUC1-tg mice. The first generation of female MMTV-PyMT (n ¼ 4) and MMTV-PyMT/hMUC1 (n ¼ 9) mice were selected and closely monitored for 6 months. We excluded female hMUC1 transgenic mice from our experimental groups because C57BL6 female hMUC1 transgenic mice did not spontaneously generate breast tumors during the experimental period. MMTV-PyMT/hMUC1 mice developed larger tumors compared with the corresponding MMTV-PyMT control mice (Figure 6a ). There was a statistically significant difference in tumor weight when MMTVPyMT/hMUC1 mice were compared with MMTVPyMT mice. Additionally, tumor occurrence was slightly higher in MMTV-PyMT/hMUC1 mice compared with the MMTV-PyMT control mice (Figure 6b ). Subsequently, we confirmed that human MUC1 affected VEGF expression in vivo. For this, spontaneous tumor tissues were stained with rabbit anti-mouse VEGF and mouse anti-human MUC1 antibodies. Human MUC1 was detected using a fluorescein isothiocyanate-conjugated anti-mouse immunoglobulin G. Mouse VEGF was detected with a phycoerythrin-conjugated antirabbit immunoglobulin G and analyzed with confocal microscopy. Immunofluorescence staining showed that nearly all cells in MMTV-PyMT/hMUC1 mouse tumors were positive for human MUC1 and mouse VEGF, but the tumor tissues from the MMTV-PyMT control mice were negative for hMUC1 and the staining for mouse VEGF was relatively weak (Figure 6c ). Additionally, MMTV-PyMT/hMUC1 mice showed significant expression of VEGF compared with the MMTV-PyMT Formalin-fixed paraffin sections were stained with anti-hMUC1 and anti-VEGF antibodies. Significant differences were evaluated using an unpaired two-tailed Student's t-test. **Po0.01 and ***Po0.001 compared with control. control mice (Figure 6d ). To confirm the role of MUC1 in angiogenesis, we stained tumors with antibody against CD31, a marker of vascular endothelial cells, and detected augmented blood vessels in spontaneous breast tumor tissues. The level of fluorescence intensity corresponding to CD31 in MMTV-PyMT/hMUC1 tumors was two times higher than that of the MMTVPyMT control tumors (Figure 6d ). These results indicate that MUC1 does not directly influence tumor cell growth. Rather, it seems that MUC1 has the ability to promote tumor angiogenesis the results in tumor growth.
Tissue microarray (TMA)
The TMA used in our study included 32 surgical specimens of breast cancer. TMA slides were subjected to immunohistochemical analysis. The slides were stained with antibodies against human MUC1 and VEGF. Representative examples of positive and negative staining for each antigen are shown in Supplementary Figure S2 . Table 1 shows the association between MUC1 and VEGF expression. Seven human breast adenocarcinoma samples lacked MUC1 and VEGF staining, and another seven cases lacked MUC1 staining while maintaining VEGF expression. Conversely, a lack of VEGF expression was never observed without concurrent loss of hMUC1 staining. The association between MUC1 and VEGF immunohistochemistry analysis was statistically significant (Pearson's w 2 test, Po0.005). In this study we suggested that MUC1 is directly involved in the regulation of tumor angiogenesis. The present data confirmed a direct association between MUC1 expressions with VEGF expression in breast cancer.
Discussion
In this study we determined the role of MUC1 in breast cancer angiogenesis. We adopted a multidisciplinary approach to identify an angiogenic signature for MUC1 and the mechanisms by which MUC1 promotes tumor growth. We found that the presence of MUC1 increases the level of VEGF expression and tumor growth in vivo. Moreover, our data showed that MUC1 activates IGF-1R/AKT and promotes tumor angiogenesis in vivo and in vitro. Our report revealed a primary mechanism for the previously reported observation that tissue levels of MUC1 are associated with cancer progression and poor prognosis in patients with a broad range of cancers. Several clinical tissue studies have reported that MUC1 is involved in tumor angiogenesis (Giatromanolaki et al., 2000; Papadopoulos et al., 2001; Hattrup and Gendler, 2006) . However, these reports are inconsistent because some evidence shows a correlation between the increased level of MUC1 expression and increases in angiogenic markers (Yin et al., 2007) . Hence, in this study we provided valuable insight into the molecular mechanisms through which MUC1 stimulates tumor angiogenesis in a breast cancer model. We found that MUC1 is able to increase the level of VEGF expression in HEK-293A cells (Figure 1 ) and breast cancer cell lines (Figure 2 ). In our search of mechanisms underlying MUC1 regulation of VEGF expression, we found that AKT and ERK1/2 are activated by MUC1 expression (Figure 3 ). This indicates an attractive mechanism whereby MUC1, which does not promote any transcriptional activity, can lead to AKT and ERK1/2 activation. Phosphorylated AKT and ERK1/2 enhances the expression of pro-angiogenesis target genes, such as VEGF (Okajima and Thorgeirsson, 2000; Pore et al., 2004) , and then promotes endothelial cell migration and proliferation, thus contributing to tumor angiogenesis. However, our results showed that AKT and ERK1/2 have distinct effects on VEGF expression. The AKT inhibition with LY-294002 was used to determine whether the AKT pathway has a role in VEGF expression. VEGF expression was almost completely abolished by LY-294002, which suggests that the AKT pathway is a positive regulator of VEGF expression. In contrast, suppression of VEGF expression by PD-98059, an ERK1/2 inhibitor, in the MUC1-expressing cancer cells was incomplete, which further implies that MUC1-mediated VEGF expression may be regulated through the AKT pathway. This may conceivably suggest distinct roles for the AKT and ERK1/2 signaling cascades in MUC1-mediated tumor development.
The IGF-1R signaling pathway has a pivotal role in the neoplastic transformation and progression of many cancers (Werner and Le Roith, 2000) . IGF-1/IGF-1R is an important regulator of energy metabolism and growth and has an important role in cancer (Pollak, 2004) . In addition, angiogenesis is a major consequence of IGF-1/IGF-1R function as IGF-1 enhances VEGF expression in cancer cells (Poulaki et al., 2003; Tang et al., 2003) . The functional effect of IGF-1R is mainly mediated through the phosphatidylinositol 3-kinase/ AKT and ERK1/2 pathways Parrizas et al., 1997; Peruzzi et al., 1999) . The interaction between MUC1 and IGF-1R is especially interesting given that IGF-1R is a potent angiogenic growth factor (Kucab and Dunn, 2003) . In this study it was suggested that MUC1 expression directly affected IGF-1R activation. To determine the relationship between MUC1 and IGF-1R, three different methods were used. First, the effects of MUC1 on IGF-1R phosphorylation ( Figures  4a and b) were examined in three different cell lines. Overall, MUC1 markedly increased the phosphorylation of IGF-1R. Second, MUC1 siRNA transfection resulted in clear inhibition of IGF-1R phosphorylation in MUC1-expressing MDA-MB-231 clones along with MCF-7 and T47D breast cancer cells that also express MUC1 (Figures 4c and d) . Finally, human MUC1-expressing spontaneous murine breast cancer cells showed significantly increased levels of IGF-1R phosphorylation compared with the control cells (Figure 4f ). These results demonstrated that both overexpression of MUC1 in MUC1-negative cell lines or loss of expression in MUC1-positive cell lines can modulate IGF-1R phosphorylation. Thus, IGF-1R might be important for allowing signaling events to be controlled by MUC1 during tumor development.
Evidence from both xenograft and spontaneous murine tumor models indicate that levels of VEGF elevated by MUC1 in cancer tissues correlate with tumor angiogenesis and progression (Kimura et al., 2000; Ferrara, 2002) . Our results indicated that MUC1 enhances xenograft tumor growth in NOD/SCID mice. Injection of a MUC1-expressing MDA-MB-231 clone into NOD/SCID mice tumors with greater weight and volume compared with a control clone ( Figure 5) . Moreover, our data demonstrated that MMTV-PyMT/ hMUC1 mice developed larger and heavier tumors, and had an increased rate of tumor occurrence compared with the MMTV-PyMT control mice ( Figure 6 ). Tumors in MMTV-PyMT/hMUC1 mice also had higher expression of VEGF than tumors from the control animals ( Figure 6c ), suggesting that MUC1 has a role in tumor growth by promoting angiogenesis. Furthermore, human breast carcinoma TMA analysis proved that the overexpression of MUC1 was dependent on VEGF expression in breast cancer (Table 1) . A significant association between MUC1 expression and VEGF expression was noted. Thus, MUC1 expression turns on the context of a primordial genetic event of angiogenic pathways. It is how IGF-1R is activated by MUC1 expression. Classically, activation of IGF-1R results from direct binding of the ligand IGF-1, leading to a downstream signaling cascade. A very interesting clue is that MUC1 directly interacts with growth factor receptors, including the endothelial growth factor receptor (Pochampalli et al., 2007b) , transforming growth factor-a receptor (Pochampalli et al., 2007a) and fibroblast growth factor receptor (Ren et al., 2006) . Results from this study confirm that MUC1 is an important regulator of IGF-1R activation during tumor angiogenesis. Thus, we presume that direct or indirect interaction of both molecules might increase the expression of VEGF, thereby contributing to the angiogenic response of breast cancer. However, further studies are needed to clarify the underlying mechanisms.
In agreement with an in vitro, an in vivo study confirmed the effect of MUC1 on angiogenesis in breast cancer. This is the first report to propose that MUC1 is crucial for the regulation of tumor angiogenesis. As summarized, data from our study revealed that phosphorylation of IGF-1R and AKT is induced by MUC1 expression. Additionally, we showed that VEGF is a downstream component of the MUC1/IGF-1R/AKT cascade, and has a potential role in tumor angiogenesis associated with MUC1.
Materials and methods
Cell lines
Human breast cancer cell lines (MDA-MB-231, HS578T and T47D), the human embryonic kidney cell line (HEK)-293A and murine endothelial cells (SVEC) (Sorokin et al., 1997; Geddis et al., 2006; Yu et al., 2007) were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). These cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM; Welgene, Seoul, Korea) supplemented with 10% fetal bovine serum (Welgene) and 1% penicillinstreptomycin (GIBCO-BRL Life Technologies; Gaithersburg, MD, USA). All cell lines were cultured at 37 1C in the presence of 5% CO 2 . Mouse primary breast cancer cells were isolated from MMTV-PyMT and MMTV-PyMT/hMUC1 doubletransgenic mice. A piece of a mammary tumor was removed from the MMTV-PyMT and MMTV-PyMT/hMUC1 mice and placed in DMEM containing 20% fetal bovine serum and 1% penicillin-streptomycin, then manually dissociated with sterilized microscope slides. The pieces were then dispersed in a cell culture dish and maintained in DMEM with 20% fetal bovine serum. Cell colonies were collected and placed into a new cell culture dish. Cells were grown for use in subsequent experiments.
Transfection
Full-length human MUC1 (MUC1) expression using a retroviral construction was prepared, as described previously (Cho et al., 2005) . Supernatants that contain MUC1 encoding retroviral particles were transduced into MDA-MB-231 and T47D human breast adenocarcinoma cell lines. Transduced MDA-MB-231 and T47D cells were cultured with 1 mg/ml of G418 (GIBCO-BRL Life Technologies) in DMEM supplemented with 10% fetal bovine serum to establish stable cell lines expressing MUC1. pcDNA3-hMUC1 DNA plasmid was prepared by subcloning full-length MUC1 cDNA containing the C-and N-termini into pcDNA3 expression vector. MUC1 plasmid was purified using the Qiagen Endofree Plasmid Midi Kit (Qiagen, Hamburg, Germany) and used for transient transfection.
Human MUC1 siRNA (5 0 -ACC AAG AGC UGC AGA GAG ATT-3 0 ) was synthesized by GenePharm (Shanghai, China). These siRNAs were used for in vitro assays after the optimal transfection conditions were determined by a fluorescein isothiocyanate-labeled scramble oligonucleotide control (5 0 -UUC UCC GAA CGU GUC ACG UTT-3 0 ; GenePharm). MUC1 and IGF-1R expression was evaluated by western blotting.
Western blotting and antibodies
Western blot analysis was performed, as described previously (Morgillo et al., 2006) . Briefly, whole-cell lysates were prepared in a modified radioimmuno precipitation assay buffer containing proteinase inhibitors and phosphatase inhibitors, as described elsewhere (Fontana et al., 2002) . Equivalent amounts of protein (20-80 mg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 6 and 10% gels and transferred to polyvinylidene fluoride membranes (Bio-Rad; Hercules, CA, USA). The blots were incubated with primary antibodies against human MUC1 (Bio-meda; Foster City, CA, USA), phosphorylated AKT (Ser-473), AKT, phosphorylated Erk1/2, Erk1/2, phosphorylated IGF-1R (Cell Signaling; Beverly, MA, USA), IGF-1R, VEGF or actin (Santa Cruz Biotechnology, Inc.; Santa Cruz, CA, USA). After washing, the blot was incubated with horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology, Inc.). The protein-antibody complexes were detected using an enhanced chemiluminescence kit (Amersham; Arlington Heights, IL, USA), according to the manufacturer's recommended protocol.
In vivo models Six-to eight-week-old female NOD/SCID mice (NOD/ LtSz-Prkdcscid/J) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and maintained under specific pathogen-free conditions. In brief, MUC1-expressing MDA-MB-231 clones or a mock control clone were subcutaneously injected (1 Â 10 7 cells in 100 ml of phosphate buffered saline) at a single dorsal site in NOD/SCID mice. The resulting tumors were measured once or twice per week for 7 weeks. Mammary gland-targeted transgenic expression of polyomavirus middle T-antigen (MMTV-PyMT) transgenic mice (C57BL/6) spontaneously develop mammary tumors at different stages ranging from hyperplasia to poorly differentiated adenocarcinoma (Guy et al., 1992) . Human MUC1 transgenic mice (hMUC1-tg) were mated with MMTV-PyMT to generate MMTV-PyMT/hMUC1 mice. Male MMTVPyMT mice were mated with female hMUC1-tg to generate female MMTV-PyMT and MMTV-PyMT/hMUC1 mice. To quantify tumor growth and angiogenic activity in mice, we observed the animals for a 6-month period and killed the mice to obtain tumors for further experiments. All animal experiments were performed after receiving approval from the Institutional Animal Care and Use Committee of Seoul National University.
VEGF quantitative enzyme-linked immunosorbent assay
The MUC1-expressing MDA-MB-231 and T47D cancer cell lines and mock control cell lines were plated in triplicate at 5 Â 10 5 cells per well in 6-well tissues culture plates. The cells were cultured in serum-free DMEM for 24 h. The serum-free cultured medium were harvested and quantified for the secreted VEGF level. The amount of secreted VEGF was determined using a commercial enzyme-linked immunosorbent assay detection kit (Komabiotech; Seoul, Korea) according to the manufacturer's instruction.
Semi-quantitative reverse transcription-PCR
For semi-quantitative reverse transcription-PCR, 1 mg of RNA was used as a template for reverse-transcription with the Prime Script 1'st strand cDNA Synthesis kit (Takara; Kyoto, Japan). PCR was carried out with 50 ng of cDNA with a PCR pre-mixture (Takara). The sequences of the primers used were as follows: b-actin (forward: 5 0 -CCT CTA TGC CAA CAC AGT GC-3 0 ; reverse: 5 0 -GTA CTC CTG CTT GCT GAT CC-3 0 ) and VEGF (forward: 5 0 -CTA CCT CCA CCA TGC CAA GT-3 0 ; reverse: 5 0 -TCT CTC CTA TGT GCT GGC CT-3 0 ).
Immunofluorescence Cells or frozen sections were fixed in 3.5%. formaldehyde at room temperature for 15 min. Permeabilization was carried out at À20 1C with methanol for 5 min. Residual methanol was washed with phosphate buffered saline. For immunofluorescence, cells were incubated overnight with primary antibodies diluted in phosphate buffered saline with 0.1% Triton X-100 and 5% bovine serum albumin. Cells were washed three times with phosphate buffered saline with 0.1% Triton X-100, then incubated with fluorescein isothiocyanate-conjugated goat anti-mouse immunoglobulin G1 (Santa Cruz Biotechnology, Inc.) or phycoerythrin-conjugated goat anti-rabbit immunoglobulin G (Santa Cruz Biotechnology, Inc.) for 2 h. 4 0 ,6-Diamidino-2-phenylindole (Santa Cruz Biotechnology, Inc.) was used to stain the nuclei for triple color confocal laser scanning microscopy analysis.
TMA and immunohistochemical analysis A total of 32 different tissues were included in a TMATMA. Mice mammary tumors or xenograft human breast cancer were fixed in 10% neutral buffered formalin and embedded in paraffin for sectioning. Immunohistochemical analysis was performed on the paraffin-embedded tissues using the standard techniques with antibodies and conditions presented in Table 2 . Appropriate formalin-fixed and paraffin-embedded negative control samples were included for each antibody and assay. Immunohistochemical analysis staining was scored as positive if any specific staining was observed in the appropriate subcellular locations.
Statistical analysis
Significant differences (Po0.05) were evaluated using an unpaired two-tailed Student's t-test. In graphical representation of the data, y-axis error bars indicate the s.d. of the data for each point marked on the graph. All experiments were repeated at least twice. 
